Novartis: UBS reiterates its advice on the stock


(CercleFinance.com) – UBS estimates that the adjustments to Kisqali production have a limited impact. The analyst confirms his purchase advice on the stock with a price target of 104 E which represents an upside prospect of 20%.

‘Manufacturing adjustments are expected to be implemented by the end of the second quarter and Natalee’s regulatory review is expected to proceed as planned,’ says UBS.

Remember that the group has revised its medium-term forecasts, to now expect net sales to increase in average annual CER of 5% over 2023-28 and a growing core operating profit margin of around 40% or more. here in 2027.

Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.

Did you like this article ? Share it with your friends using the buttons below.





Facebook


Linkedin


E-mail





Source link -85